MDT-AP-2822
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 12
- sex
- F
- new_clusters
- S2
- umap1_2d
- -1.182511312
- umap2_2d
- -10.93238005
- umap1_3d
- -2.936473853
- umap2_3d
- -0.619207006
- umap3_3d
- 5.584080298
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.510
- TNFA_SIGNALING_VIA_NFKB+0.390
- MYC_TARGETS_V2+0.380
- INTERFERON_ALPHA_RESPONSE+0.360
- ANGIOGENESIS+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- ALLOGRAFT_REJECTION+0.320
- INFLAMMATORY_RESPONSE+0.310
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- HEME_METABOLISM-0.110
- HEDGEHOG_SIGNALING-0.090
- SPERMATOGENESIS-0.090
- MITOTIC_SPINDLE-0.050
- PI3K_AKT_MTOR_SIGNALING-0.040
- APICAL_JUNCTION-0.010
- PANCREAS_BETA_CELLS+0.010
- PEROXISOME+0.040
- PROTEIN_SECRETION+0.040
- WNT_BETA_CATENIN_SIGNALING+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.926 |
| 2 | MDT-AP-1185 | Med | Medulloblastoma | 0.925 |
| 3 | MDT-AP-1106 | Med | Medulloblastoma | 0.918 |
| 4 | MDT-AP-2001 | Med | Medulloblastoma | 0.918 |
| 5 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.915 |
| 6 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.907 |
| 7 | MDT-AP-0348 | Med | Medulloblastoma | 0.907 |
| 8 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.905 |
| 9 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.905 |
| 10 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |